AstraZeneca Commits $50 Billion to US Manufacturing and R&D Efforts by 2030

July 22, 2025

The investment is highlighted by a state-of-the-art API facility in Virginia and expansions across multiple states.

AstraZeneca revealed that alongside the $3.5 billion announced in November of last year,1 it will be investing $50 billion in the United States by the year 2030.2 The financial commitment is expected to be centered around medication manufacturing and R&D, representing what the company describes as the largest single manufacturing investment in the world. Tens of thousands of new, skilled positions across the country will be opening up in the process.

Virginia manufacturing plant to anchor US expansion

The focal point of this announcement is a multi-billion-dollar manufacturing plant in the Commonwealth of Virginia that is expected to produce drug substances—also known as active pharmaceutical ingredients (APIs)—for AstraZeneca’s weight management and metabolic portfolio. This features oral GLP-1s, oral PCSK9, and baxdrostat, along with combination small molecule products. The new state-of-the-art center will be producing small molecules, peptides and oligonucleotides.

Artificial intelligence, data analytics, and automation will be enhancing the production process—the combination of these multiple investments go toward meeting the company’s goal of establishing $80 billion in total revenue by 2030. A projected 50% of that would be produced in the United States.

“For decades, Americans have been reliant on foreign supply of key pharmaceutical products. President Trump and our nation’s new tariff policies are focused on ending this structural weakness,” said Howard Lutnick, US Secretary of Commerce. “We are proud that AstraZeneca has made the decision to bring substantial pharmaceutical production to our shores. This historic investment is bringing tens of thousands of jobs to the US and will ensure medicine sold in our country is produced right here.”

Key Takeaways

AstraZeneca plans to invest $50 billion by 2030 in US-based drug manufacturing and R&D, marking its largest single manufacturing investment globally.
A new state-of-the-art facility in Virginia will produce active pharmaceutical ingredients (APIs) for weight management and metabolic treatments, leveraging AI, automation, and data analytics.
This move aligns with broader industry efforts to reshore pharmaceutical manufacturing to the US, as potential tariffs of up to 200% on imports loom under Trump’s trade policies.

Tariffs drive reshoring of pharma manufacturing

Lutnick is referring to Trump’s efforts to reshore pharma manufacturing to the United States by enacting potential pharma tariffs, which are believed to be hitting the sector by the beginning of August.2 He described it as being a “low tariff” that would slowly increase over the course of approximately a year.

Multi-state investments to drive innovation

Trump had previously stated that import taxes of up to 200% could be forthcoming, but it is not yet clear as to if and when those could take effect, if at all. Various companies—such as Regeneron, Roche, Merck, and Thermo Fisher Scientific—have also started the reshore process to avoid the impending tariffs.3 The Thermo acquisition involves Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, which is anticipated to enhance its US-based sterile fill-finish capacity.

As for AstaZeneca’s aforementioned $50 billion investment, upcoming projects will consist of:

A new R&D center in Kendall Square, Cambridge, MA
Cell therapy manufacturing plants in Rockville, MD and Tarzana, CA
Expansion of the R&D plant in Gaithersburg, MD
Specialty manufacturing expansion in Coppell, TX
Continuous manufacturing expansion in Mount Vernon, IN
New sites to supply clinical trials (to be announced)
Expanding R&D investment in novel medicines

AstraZeneca CEO Pascal Soriot emphasized the company’s long-term vision and commitment to US biopharmaceutical innovation, stating that “today’s announcement underpins our belief in America’s innovation in biopharmaceuticals and our commitment to the millions of patients who need our medicines in America and globally. It will also support our ambition to reach $80 billion in revenue by 2030. I look forward to partnering with Governor Youngkin and his team to work on our largest single manufacturing investment ever. It reflects the Commonwealth of Virginia’s desire to create highly-skilled jobs in science and technology, and will strengthen the country’s domestic supply chain for medicines.”

References

1. AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States. AstraZeneca. November 12, 2024. Accessed July 22, 2025. https://www.astrazeneca.com/media-centre/press-releases/2024/astrazeneca-invests-3bn-500mn-in-us.html

2. AstraZeneca plans to invest $50 billion in America for medicines manufacturing and R&D. AstraZeneca. July 21, 2025. Accessed July 22, 2025. https://www.astrazeneca-us.com/media/press-releases/2025/AstraZeneca-plans-to-invest-50-billion-in-America-for-medicines-manufacturing-and-R-and-D.html

3. Saraceno N. Trump Says Pharma Industry Should Expect Tariffs by Aug. 1. Pharmaceutical Commerce. July 21, 2025. Accessed July 22, 2025. https://www.pharmaceuticalcommerce.com/view/trump-pharma-industry-tariffs-by-aug-1